Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

詳細情報 詳細情報について

• CRID

  1364233268525448448

• DOI

  10.1093/annonc/mdy424.028

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753419504197?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753419504197?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy424.028/26140488/mdy424.028.pdf

• データソース種別

  • Crossref